SCHEMBL4937480

SCHEMBL4937480

COC(=O)c1ccnc(C(=O)N(C)C)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.54
KDM4C Q9H3R0 3/20 0.54
KDM6B O15054 2/20 0.54
KDM5C P41229 2/20 0.54
KDM2A Q9Y2K7 2/20 0.54
KDM3A Q9Y4C1 2/20 0.54
ALOX15 P16050 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
JMJD6 Q6NYC1 1/20 0.48
HTT P42858 2/20 0.44
RAB9A P51151 2/20 0.44
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
MAPK1 P28482 2/20 0.44
ALDH1A1 P00352 4/20 0.43
MAPT P10636 3/20 0.43
KDM5B Q9UGL1 3/20 0.43
KDM5A P29375 2/20 0.43
TET3 O43151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL70350 0.84 KDM4E (0.62) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL30065796 0.84 KDM4E (0.62) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL30378954 0.81 KDM4E (0.58) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL30779113 0.81 KDM4E (0.68) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL475565 0.81 KDM4E (0.68) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL1759313 0.81 KDM4E (0.58) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL17819893 0.81 FTO (0.67) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL29066364 0.80 ALDH1A1 (0.46) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL1759324 0.80 KDM4E (0.57) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL13950719 0.80 KDM4E (0.57) KDM4EKDM4CKDM6BKDM5CKDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3042900-B1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF FUJIFILM CORP (JP) 2020-09-23 EP disclosed
US-9586951-B2 Morpholine derivative or salt thereof FUJIFILM CORPORATION (JP) 2017-03-07 US disclosed
US-9586951-B2 Morpholine derivative or salt thereof FUJIFILM CORPORATION (JP) 2017-03-07 US disclosed
US-9586951-B2 Morpholine derivative or salt thereof FUJIFILM CORPORATION (JP) 2017-03-07 US disclosed
EP-3042900-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF Fujifilm Corporation (JP) 2016-07-13 EP disclosed
US-20160168139-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2016-06-16 US disclosed
US-20160168139-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2016-06-16 US disclosed
US-20160168139-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2016-06-16 US disclosed
US-20080293696-A1 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents BAYER PHARMACEUTICALS CORPORATION (US) 2008-11-27 US disclosed
US-20080293696-A1 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents BAYER PHARMACEUTICALS CORPORATION (US) 2008-11-27 US disclosed
US-20080293696-A1 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents BAYER PHARMACEUTICALS CORPORATION (US) 2008-11-27 US disclosed
EP-1765811-A2 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS Bayer Pharmaceuticals Corporation (US) 2007-03-28 EP disclosed
WO-2006023707-A2 2-AMINOTHIOPHENECARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS BAYER PHARMACEUTICALS CORPORATION (US) 2006-03-02 WO disclosed
WO-2006002383-A2 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS BAYER PHARMACEUTICALS CORPORATION (US) 2006-01-05 WO disclosed
EP-0585328-B1 SUBSTITUTED 3-AMINOQUINUCLIDINES PFIZER (US) 2002-01-09 EP disclosed
US-5852038-A Substituted 3-aminoquinuclidines PFIZER INC (US) 1998-12-22 US disclosed
US-5716965-A Substituted 3-aminoquinuclidines PFIZER INC. (US) 1998-02-10 US disclosed
EP-0585328-A1 SUBSTITUTED 3-AMINOQUINUCLIDINES PFIZER INC. (US) 1994-03-09 EP disclosed
WO-1992020676-A1 SUBSTITUTED 3-AMINOQUINUCLIDINES PFIZER INC. (US) 1992-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168139-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF PRMT7, RBBP7, RER1 KDM4E 2666/4885KDM4C 756/4885KDM6B 679/4885
US-20080293696-A1 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents ABCC3, HCCS, ABCC2 KDM4E 975/4885KDM4C 568/4885KDM6B 1624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.